Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2026-06-13 @ 8:38 PM
Study NCT ID:
NCT01915602
Status:
COMPLETED
Last Update Posted:
2021-04-08
First Post:
2013-07-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Sponsor:
Bayer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
16728
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None